{"id":"shr-1501-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to PD-L1 on tumor cells and immune cells, SHR-1501 prevents the engagement of PD-L1 with its receptors on T cells, which normally suppresses immune activation. This blockade restores T-cell proliferation, activation, and cytotoxic function, allowing the immune system to recognize and attack cancer cells more effectively. The drug is designed to enhance endogenous anti-tumor immunity across multiple cancer types.","oneSentence":"SHR-1501 is a recombinant human anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and PD-1/B7-1, thereby releasing immune checkpoint inhibition and enhancing anti-tumor T-cell responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:30.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-1501 for Injection","genericName":"SHR-1501 for Injection","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-1501 for Injection is being studied in a clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC) that is unresponsive to BCG treatment. The study compares the combination of SHR-1501 with BCG to investigator-selected chemotherapy in patients with NMIBC.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}